A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Description

This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.

Conditions

Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

Talk to us

Study Overview

On this page

Study Details

Study overview

This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.

A Phase 1 First in Human Study of ARV-393 in Adult Participants With Advanced Non-Hodgkin's Lymphoma

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Condition
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Intervention / Treatment

-

Contacts and Locations

Detroit

Clinical Trial Site, Detroit, Michigan, United States, 48201

New Brunswick

Clinical Trial Site, New Brunswick, New Jersey, United States, 10065

New York

Clinical Trial Site, New York, New York, United States, 10016

Cleveland

Clinical Trial Site, Cleveland, Ohio, United States, 44122

Nashville

Clinical Trial Site, Nashville, Tennessee, United States, 37203

Houston

Clinical Trial Site, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Eligible participants aged ≥18 years.
  • * Have relapsed/refractory mature B-cell non-Hodgkin lymphoma (NHL) and ≥2 prior systemic therapies, or histologically confirmed AITL that has recurred or progressed following institutional standard-of-care therapy.
  • * Participants must also have ≥1 measurable lesion at study entry
  • * Eastern Cooperative Oncology Group performance status of 0 or 1,
  • * Freshly biopsied or archival tumor tissue available,
  • * Participants with adequate organ function,
  • * Participants must accept and follow pregnancy prevention guidance.
  • * No prior allogeneic stem cell transplant or solid organ transplantation, Autologous stem cell transplant, must not have occurred ≤100 days, previous CAR T-cell therapy ≤60 days, radiotherapy ≤ 2 weeks, systemic anticancer treatment ≤ 5 half-lives or 4 weeks, prior to ARV-393 treatment initiation.
  • * Participants must not have significant acute or chronic medical illness, including hypereosinophilic syndrome, active interstitial lung disease or pneumonitis, active or uncontrolled infection, or the presence of laboratory abnormalities, that places participants at unacceptable risk if participating in this study.
  • * Participants with an inability to comply with listed prohibited treatments.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Arvinas Inc.,

Study Record Dates

2025-12